HuagongsheHuagongshe Chemie-Druckbericht · Nur für Forschungszwecke

HCID 71464713Erstellt: 2. November 2026

Acoramidis

Acoramidis · 3-(3-(3,5-dimethyl-1H-pyrazol-4-yl)propoxy)-4-fluorobenzoic acid · AG10,AG 10 · Acoramidis (AG-10) · AG-10 1446711-81-4 · AG-10, 10 mM in DMSO · Benzoic acid, 3-[3-(3,5-dimethyl-1H-pyrazol-4-yl)propoxy]-4-fluoro- · 3-[3-(3,5-Dimethyl-1H-pyrazol-4-yl)propoxy]-4-fluorobenzoic acid (ACI)

https://huagongshe.com/de/chemical/71464713

Identifikatoren & physikalische Daten

CAS No.	1446711-81-4
Summenformel	C15H17FN2O3
Durchschnittliche Molmasse	292,3 g/mol
Monoisotopische Masse	292,12232057 g/mol
SMILES	Cc1n[nH]c(C)c1CCCOc1cc(C(=O)O)ccc1F
InChIKey	WBFUHHBPNXWNCC-UHFFFAOYSA-N
PubChem CID	71464713
ChEMBL	CHEMBL3940890
EC No.	950-296-9
DTXSID	DTXSID501358946

Chemische & physikalische Eigenschaften

XLogP	2,9
Polarare Oberfläche (TPSA)	75,2
H-Brücken-Donoren	2
H-Brücken-Akzeptoren	5
Frei drehbare Bindungen	6
Schwere Atome	21
Formalladung	0
Komplexität	356
Löslichkeit	≥12 micrograms/mLDMSO: Soluble: =10 mg/mlEthanol: Slightly soluble: 0.1-1 mg/ml
Human Drugs	Breast FeedingLactationMilk, HumanEMA approved medicines: Human medicine
Siedepunkt	542.5±50.0 °C(Predicted)
Dichte	1.282±0.06 g/cm3(Predicted)
pKa (Säurekonstante)	3.98±0.10(Predicted)
Aggregatzustand	Solid
Farbe	White to off-white
InChI	InChI=1S/C15H17FN2O3/c1-9-12(10(2)18-17-9)4-3-7-21-14-8-11(15(19)20)5-6-13(14)16/h5-6,8H,3-4,7H2,1-2H3,(H,17,18)(H,19,20)
InChIKey	WBFUHHBPNXWNCC-UHFFFAOYSA-N
SMILES	C(O)(=O)C1=CC=C(F)C(OCCCC2=C(C)NN=C2C)=C1

Sicherheit & Vorschriften

GHS-Einstufung	WarningH315 (100%): Causes skin irritation [Warning Skin corrosion/irritation]P261, P264, P264+P265, P271, P280, P302+P352, P304+P340, P305+P351+P338, P319, P321, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory.
Hazard Classes and Categories	Skin Irrit. 2 (100%)
Hepatotoxicity	In the registration trial of acoramidis, transient mild ALT and AST elevations were not uncommon, but elevations in ALT above 3 times ULN were infrequent and no more common with acoramidis than placebo (0.9% vs 0.5%), most of which were attributed to heart failure or its treatment. No patient required drug discontinuation because of liver test abnormalities and none developed clinically apparent liver injury or elevations in serum aminotransferases accompanied by jaundice. Since its approval, clinical experience with acoramidis has been limited, but there have been no published case reports of clinically apparent liver injury attributed to its use.
Effects During Pregnancy and Lactation	◉ Summary of Use during Lactation
Alarmwort	Warnung
Gefahrenhinweise	Code Gefahrenhinweise Gefahrenklasse Abteilung Alarmwort Symbol P-Code H315

Acoramidis

CAS No.

1446711-81-4

Summenformel

C15H17FN2O3

Durchschnittliche Molmasse

292,3 g/mol

Monoisotopische Masse

292,12232057 g/mol

SMILES

Cc1n[nH]c(C)c1CCCOc1cc(C(=O)O)ccc1F

InChIKey

WBFUHHBPNXWNCC-UHFFFAOYSA-N

PubChem CID

71464713

ChEMBL

CHEMBL3940890

EC No.

950-296-9

DTXSID

DTXSID501358946

Chemische & physikalische Eigenschaften

XLogP

2,9

Polarare Oberfläche (TPSA)

75,2

H-Brücken-Donoren

H-Brücken-Akzeptoren

Frei drehbare Bindungen

Schwere Atome

Formalladung

Komplexität

356

Löslichkeit

≥12 micrograms/mLDMSO: Soluble: =10 mg/mlEthanol: Slightly soluble: 0.1-1 mg/ml

Human Drugs

Breast FeedingLactationMilk, HumanEMA approved medicines: Human medicine

Siedepunkt

542.5±50.0 °C(Predicted)

Dichte

1.282±0.06 g/cm3(Predicted)

pKa (Säurekonstante)

3.98±0.10(Predicted)

Aggregatzustand

Solid

Farbe

White to off-white

InChI

InChI=1S/C15H17FN2O3/c1-9-12(10(2)18-17-9)4-3-7-21-14-8-11(15(19)20)5-6-13(14)16/h5-6,8H,3-4,7H2,1-2H3,(H,17,18)(H,19,20)

InChIKey

WBFUHHBPNXWNCC-UHFFFAOYSA-N

SMILES

C(O)(=O)C1=CC=C(F)C(OCCCC2=C(C)NN=C2C)=C1

Sicherheit & Vorschriften

GHS-Einstufung

WarningH315 (100%): Causes skin irritation [Warning Skin corrosion/irritation]P261, P264, P264+P265, P271, P280, P302+P352, P304+P340, P305+P351+P338, P319, P321, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory.

Hazard Classes and Categories

Skin Irrit. 2 (100%)

Hepatotoxicity

In the registration trial of acoramidis, transient mild ALT and AST elevations were not uncommon, but elevations in ALT above 3 times ULN were infrequent and no more common with acoramidis than placebo (0.9% vs 0.5%), most of which were attributed to heart failure or its treatment. No patient required drug discontinuation because of liver test abnormalities and none developed clinically apparent liver injury or elevations in serum aminotransferases accompanied by jaundice. Since its approval, clinical experience with acoramidis has been limited, but there have been no published case reports of clinically apparent liver injury attributed to its use.

Effects During Pregnancy and Lactation

◉ Summary of Use during Lactation

Alarmwort

Warnung

Gefahrenhinweise

Code Gefahrenhinweise Gefahrenklasse Abteilung Alarmwort Symbol P-Code H315